|
IQVIA |
CRA¸ðÁý°ø°í_IQVIA (urgent position) new
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
¢ß¾¾¿£¾Ë¸®¼Ä¡ Research ºÎ»ê »ç¹«¼Ò CO ÆÀ [°æ·Â] CRA ä
ºÎ»ê µ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.27 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
[¾¾¿£¾Ë¸®¼Ä¡] Clinical Trial Metadata Researcher
¼¿ï ³ë¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.12 |
|
|
(ÁÖ)·¹¸ð³Ø½º |
ÀÓ»ó »ó½Ã ä¿ë°ø°í
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
03.28 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) °¢ ºÎ¹® ä¿ë (ÃÑ 14°³ posit
¼¿ï °³²±¸, °æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.23 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Project Coordinator ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.23 |
|
|
½Ã¹ÍÄÚ¸®¾Æ |
[½Ã¹ÍÄÚ¸®¾Æ] CRA(I, II, Sr.) ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
09.10 |
|
|
È޸չ븮 |
ÀÓ»ó ½ºÆä¼È¸®½ºÆ®
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.03 |
|
|
½Ã¹ÍÄÚ¸®¾Æ |
[½Ã¹ÍÄÚ¸®¾Æ] Medical Writing Leader ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
09.10 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] In-house CRA ä¿ë°ø°í
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.03 |
|
|
¾¾¿£¾Ë¸®¼Ä¡ |
CRO [¾¾¿£¾Ë¸®¼Ä¡] DOÆÀ CDMA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.04 |
|
|
Çѱ¹Æ丵Á¦¾à(ÁÖ) |
Medical CRA °è¾àÁ÷ (ASAP-2021.10 2³â)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.14 |
|
|
(ÁÖ)¿Ã¸®ºêÇコÄɾî |
ÀÓ»ó »ó´ã Äݼ¾ÅÍ Á¤±ÔÁ÷ ä¿ë (½ÅÀÔÁö¿ø°¡´É)
°æ±â ¿ëÀνà | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.19 |
|
|
(ÁÖ)À¯Æ¿·º½º |
ºñÀÓ»óÆÀ(¿¬±¸) ä¿ë
¼¿ï ±Ýõ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.17 |
|
|
¸ÞµðÅ©·Î½ºÅ¸(ÁÖ) |
[±¹³»CRO ÀÓ»ó½ÃÇè¼öŹ±â°ü] Åë°èºÐ¼®ÆÀ0¸í ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.05 |
|